Pacira BioSciences, Inc. Insider Trading Activity
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Pacira BioSciences (PCRX) disclosed that its Chief Financial Officer sold 12,060 shares of common stock at $22.09 per share on 11/10/2025.
The transaction was executed under a Rule 10b5-1 trading plan. After this sale, the CFO beneficially owns 56,250 shares, held directly.
Insider Trade Summary
Net Seller: 12,060 shares
Net Sell
1 txn
Insider
Cross Shawn
Role
Chief Financial Officer
Sold
12,060 shs ($266K)
Share of Position Sold
17.7%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 12,060 | $22.09 | $266K |
Holdings After Transaction:
Common Stock — 56,250 shares (Direct)
Holdings Before and After:
Common Stock, 68,310 to 56,250 shares (Direct)
Footnotes (1)
- F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
AI-generated analysis. How Rhea-AI works. Not financial advice.